Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
As somebody else has already said, it's a technical breakout. Traders are piling in and will sell out once they're made their profit. However, we should find our new resistance to be around 188p assuming no fundamental changes.
I've also bought in here as of last week. Expect to see lots more like me arriving soon!
I hold SNG and AVCT. I've did hold NCYT and ODX but quite frankly, I don't believe in their products so I've taken profits and moved on. Antibody and lab testing isn't going to get us out of trouble.
I sold out too early on the last SNG rise. It started to drop back from around a quid, so having more than doubled my money I bailed out. It then proceeded to rise again and carried on way beyond two pounds. That was an error, but never mind. Can't complain. I've recently bought back in, think it was around 150 I paid as it was very oversold and will surely re-rate when news lands.
Rapid tests to siginificantly reduce the spread and a highly effective treatment for the few people who do end up in hospital... that's a winning combination.
I bought in here at 40p several months ago and have a very large number of shares. I still believe the biggest rise is yet to come.
Whilst we are on the subject of cross ramping, I've recently taken a large position in BIDS. Much like with Avacta, I think I've got in early on that one before the masses arrive. Shameless plug, sorry.
This isn't surprising really. There's been a lot of talk about how there's a rising case count but very few people are in hospital and the deaths remain relatively low. It takes time for disease to spread, people to become ill enough to be hospitalised and then, in some very sad cases, pass away. It seems the public and even some media outlets don't understand this even though it's common sense?
Unfortunately it stands to reason that with the rapidly rising case count hospital admissions are going to rise and those will in turn be followed by deaths. Lets hope SNG001 gets to market as soon as possible.
I'm looking to buy some ODX tomorrow as IMO it's likely the rumours of ODX manfacturing for AVCT will transpire to be true. With RTC members BBI and Abbingdon already signed up, it would be strange not to see ODX on board.
All the current indications are that AVCT will be the test primarily used for moonshot. Not much is known about Mologics LFA, but even if successful will they will have the same hurdles as AVCT, but with the availability of reagents to overcome too. Not only does it need to be possible to produce a reagent at scale, it also needs to be robust. AVCT don't have the latter problem due to their Affimer reagents. With competitors dropping out of saliva and moving to swabs, or having low sensitivity like the Korean test which has been on the news this week - perhaps Affimers will transpire to be the element which makes a saliva LFA possible.
Released last night (scroll down a bit). Stolen from AVCT board.
https://www.thisismoney.co.uk/money/markets/article-8801981/STOCK-WATCH-Martin-Sorrell-set-blockbuster-deal.html
If AVCT are successful + if ODX are manfacturing + if the Gov proceed with Moonshot (all of which are very likely in my opinion)... ODX will certainly be very pleased they invested in all that new kit to increase their capacity! Those machines will be running around the clock...
Exactly PL75, not difficult to join the dots on this. Exciting few weeks ahead (I know we've been saying that a while, but now it finally seems to be true!)
Anyway, I've clogged up the board enough tonight. Off for a late gym session. Have a good weekend everyone.
I'm tempted to buy some ODX as I would be very surprised if they didn't come onboard as a manfacturing partner. I wouldn't be surprised if we had that as an RNS within the next couple of weeks. Low market cap at present, £167m.
Potential for a big rise over there if a partnership is announced with Avacta IMO. Failing that, they'll still sell a few antibody tests and their food intolerence stuff looks good too.
The RTC is University of Oxford, Abingdon Health, Omega Diagnostics, BBI and CIGA.
We are on CONDOR, but we are not in the RTC. I imagine the original reason for this being that we are working with an American firm called Cytiva who are a serious pharma player, owned by Danaher. Cytiva helped to develop the LFA and are supplying a component (the strip).
BBI and Abingdon (RTC members) are lined up to produce our antigen tests. There's also rumoured discussions with ODX and they might be on board sooon too. So that's probably where your confusion is coming from.
The Gov are looking to indentify infectious people and antibody testing cannot meet that need. ODX might be manufacturing an antigen test by Mologic, but nothing is known about the status and progress of that test aside from some trials at Heathrow. I covered this in one of my earlier posts.
Silles:
- Nobody knows to what extent one gains immunity and how long it lasts
-Immunity passports, I covered this earlier. Would create an absolute mess. Very obvious what would happen.
- Mass screening will be done with antigen tests (see moonshot info and my earlier post on infectious period)
- Antigen testing is better for this, again for the reasons I stated earlier. Antibodies are produced around 7 days after showing symptoms. By this time, you are past the most infectious period anyway. Avacta are aiming to detect Covid-19 2 days before symptoms show... so that's around 9 days sooner than an antibody test.
The Gov narrative has changed a lot over the last few months, there's no getting away from that. As sleepydave has said, all companies with a decent test will do okay.
If/when Avacta pull this off - the landscape of testing will change very quickly. Even more so if the Gov proceed with moonshot.
In MY OPINION (lets be clear on that before somebody gives me a bashing), if/when Avacta release their test - all other testing stocks will make a nosedive as this realisation dawns on people. I hold NCYT and SNG as Covid plays, but I intend to be well clear of NCYT shortly.
Okay - well lets re-visit this thread in a few weeks or months then and see how it's played out.
If everybody is taking regular antigen tests as part of moonshot - we'll know largely who's had Covid-19 and who hasn't. (Okay, there will be some asymptomatic carriers and a few will slip through the cracks.) Couple this to an app and the Government will have their statistics from the antigen tests which have already been taken.
My point is they won't stop the spread and very few people are going to take an antibody test just so the Government can gather some statistics - espcially after their terrible handling of this crisis and very little public confidence.
It's all good and well making the tests, but when the Goverment are clearly stating (as per your link) that theres nothing for the user to gain other than perhaps satisfying their curiousity and being a number to the Gov - people are not going to be lining up to take them. Maybe people within the healthcare sectors, but not general public. All IMO of course.
gkb47, extract from you own link:
"A positive result means the test did detect COVID-19 coronavirus antibodies so it is likely you’ve had coronavirus before (even if you can’t recall having symptoms). It is not possible to say when.
It does not mean you are guaranteed to be immune (protected) from further infection. You might get the virus again.
It does not mean you cannot spread the virus to others."
gkb47, IMO there's been a huge change of direction away from antibody tests and towards antigen tests since the RTC was set up at the beggining of the year. Not a full U-turn, but there's no question the UK Gov want a rapid antigen test and are much less interested in a rapid antibody test.
The article you posted states:
"In total, the UK-RTC can manufacture 10m tests within a six-month period."
That is a small amount in comparison to the quanities that Avacta are lining manufacturing partners to produce.